Full-Time

Validation Engineer I

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Hyderabad, Telangana, India

In Person

Category
QA & Testing
Quality Assurance
Requirements
  • Master's degree / Bachelor's degree and 5 to 9 years of Life Science/Biotechnology/Pharmacology/Information Systems experience
Responsibilities
  • Monitor, test, and resolve issues related to case intake and case processing across multiple systems.
  • Work closely with internal teams, external vendors, and business partners to address dependencies and resolve bottlenecks for critical issues
  • Ownership in the development of test plans, scenarios to ensure robust validation of system updates, patches and new features
  • Create test scripts, perform regression & functional testing to verify the changes do not negatively impact existing system functionality
Desired Qualifications
  • Experience in user requirements and acceptance criteria in agile project management systems such as JIRA and identification and execution of scripts.
  • Experience in management of test plan, test protocols, defect management, and requirements traceability matrix
  • Hands-on experience with the ITIL framework and methodologies like (Scrum).
  • Hands on experience in HP ALM, JIRA, Visio, document management systems (e.g: Veeva) and Service Now.
  • Experience of DevOps, Continuous Integration, and Continuous Delivery methodology, and CRM systems
  • Excellent communication skills and the ability to collaborate with Product Managers and business collaborators to define scope and value for new developments
  • Excellent analytical and solving skills
  • Strong verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • High degree of initiative and self-motivation
  • Team-oriented, with a focus on achieving team goals

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.